Publications by authors named "Dominik Richard"

Claim this Profile
E
Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).
Nick H Kim, Richard Channick, Marion Delcroix, Michael Madani, Joanna Pepke-Zaba, Dominik Richard

Eur Respir J· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Hossein-Ardeschir Ghofrani, Gérald Simonneau, Andrea M D'Armini, Peter Fedullo, Luke S Howard, Dominik Richard

Lancet Respir Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Hossein-Ardeschir Ghofrani, Gérald Simonneau, Andrea M D'Armini, Peter Fedullo, Luke S Howard, Dominik Richard

Lancet Respir Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
Naomi Schlesinger, Rieke E Alten, Thomas Bardin, H Ralph Schumacher, Mark Bloch, Dominik Richard

Ann Rheum Dis· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.
Naomi Schlesinger, Marc De Meulemeester, Andrey Pikhlak, A Eftal Yücel, Dominik Richard

Arthritis Res Ther· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
Alexander So, Marc De Meulemeester, Andrey Pikhlak, A Eftal Yücel, Dominik Richard

Arthritis Rheum· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
Thomas M MacDonald, Jean-Yves Reginster, Thomas W Littlejohn, Dominik Richard, Karine Lheritier

J Hypertens· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Christopher J Hawkey, Wilfred M Weinstein, Walter Smalley, Xavier Gitton, Peter Sallstig, Dominik Richard

Gastroenterology· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Christopher J Hawkey, Xavier Gitton, Godehard Hoexter, Dominik Richard, Wilfred M Weinstein

Clin Gastroenterol Hepatol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis